The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

8 May 2017 10:03

RNS Number : 4581E
Diurnal Group PLC
08 May 2017
 

8 May 2017

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations.

 

On 8 May 2017 the following par value options over ordinary shares of 5 pence in Diurnal were granted under the Diurnal Group plc Long Term Incentive Plan (the "Plan") to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total no. of shares under award

Type of awards

Richard Bungay

404,762

Performance Share Award

 

The performance share awards will ordinarily vest no earlier than 8 November 2019 subject to the grantee's continued service and to the extent to which the performance conditions set for the awards are satisfied. Such awards may potentially vest until 8 November 2021.

 

The awards were granted under award agreements that incorporated the terms of the Plan and comprised a mix of tax-favoured 'EMI' awards and non-tax favoured awards.

 

The exercise price payable per share under award is par value presently being 5 pence per ordinary share.

 

Details of the full notifications received by the Company are set out below:

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Richard Bungay

2

Reason for Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial Announcement

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Diurnal Group plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each in Diurnal Group plc

GB00BDB6Q760

b)

Nature of the transaction

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

EMI performance share award over 198,412 ordinary shares

 

Non-EMI performance share award over 206,350 ordinary shares.

 

The performance share award will ordinarily vest no earlier than 8 November 2019 subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until 8 November 2021.

 

The exercise price payable per share under award is par value presently being 5 pence per ordinary share.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

198,412

Nil

206,350

d)

Aggregated information

- Aggregated volume

- Price

Award over total of 404,762 ordinary shares. Nil price payable for grant.

e)

Date of the transaction

8 May 2017

f)

Place of the transaction

Outside a trading venue

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

Panmure Gordon (UK) Limited (Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley / Duncan Monteith

Corporate Broking: Tom Salvesen

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHSSFSUAFWSESI
Date   Source Headline
17th Sep 202012:40 pmEQSHardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
15th Sep 20207:00 amRNSResults for the year ended 30 June 2020
11th Sep 20207:00 amRNSShares and AJ Bell Investor Evening Webinar
3rd Sep 20205:33 pmRNSHoldings in Company
3rd Sep 20207:00 amRNSTwo further marketing and distribution agreements
27th Aug 20207:00 amRNSRichard Ross receives honour by Endocrine Society
20th Aug 20207:15 amEQSHardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
19th Aug 202010:00 amRNSNotice of Full Year Results
13th Aug 20202:06 pmRNSSecond Price Monitoring Extn
13th Aug 20202:00 pmRNSPrice Monitoring Extension
13th Aug 20207:15 amEQSHardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
10th Aug 20209:14 amRNSHolding(s) in Company
10th Aug 20207:00 amRNSAlkindi approved in Australia
5th Aug 20207:00 amRNSAlkindi approved in Israel
30th Jul 20204:41 pmRNSSecond Price Monitoring Extn
30th Jul 20204:35 pmRNSPrice Monitoring Extension
30th Jul 20202:06 pmRNSSecond Price Monitoring Extn
30th Jul 20202:00 pmRNSPrice Monitoring Extension
30th Jul 202011:05 amRNSSecond Price Monitoring Extn
30th Jul 202011:00 amRNSPrice Monitoring Extension
30th Jul 20207:01 amRNSBusiness and trading update
30th Jul 20207:00 amRNSPositive DITEST Regulatory Meeting with US FDA
29th Jul 20204:41 pmRNSSecond Price Monitoring Extn
29th Jul 20204:36 pmRNSPrice Monitoring Extension
15th Jul 20201:04 pmRNSDirector Dealings
13th Jul 20201:29 pmRNSDirector Dealings and Issue of Equity
13th Jul 20201:28 pmRNSGrant of Deferred Share Awards
26th Jun 20202:29 pmRNSDirector Dealings
9th Jun 20207:00 amRNSChronocort Phase 3 data at ENDO Online 2020
29th May 20207:00 amRNSChange of Adviser
30th Apr 20209:05 amRNSSecond Price Monitoring Extn
30th Apr 20209:00 amRNSPrice Monitoring Extension
21st Apr 202010:05 amRNSDirector Dealings and Issue of Equity
16th Apr 20202:23 pmRNSDirector Dealings
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSOperational Update
6th Apr 20209:21 amRNSDirector Dealings
1st Apr 20207:00 amRNSChronocort MAA Passes Validation Stage with EMA
30th Mar 20206:18 pmRNSHolding(s) in Company
30th Mar 20203:05 pmEQSHardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
27th Mar 20205:26 pmRNSHolding(s) in Company
27th Mar 20209:17 amRNSDirector Dealings
27th Mar 20207:00 amRNSUS Licencing Agreement with Eton Pharmaceuticals
26th Mar 20202:05 pmRNSSecond Price Monitoring Extn
26th Mar 20202:00 pmRNSPrice Monitoring Extension
25th Mar 20202:47 pmRNSResult of General Meeting and Issue of Equity
20th Mar 20204:48 pmRNSSecond Price Monitoring Extn
20th Mar 20204:39 pmRNSPrice Monitoring Extension
6th Mar 20204:55 pmRNSResult of Placing and Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.